THCT · As filed with the SEC
THC Therapeutics cash flow statement, by fiscal year
The statement as THC Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENT OF CASH FLOWS · USD
| USD | FY2024 Year ended Jul 31, 2024 | FY2023 Year ended Jul 31, 2023 | FY2022 Year ended Jul 31, 2022 | FY2021 Year ended Jul 31, 2021 | FY2020 Year ended Jul 31, 2020 | Year ended Jul 31, 2019 Year ended Jul 31, 2019 | FY2013 Year ended Jul 31, 2013 | FY2012 Year ended Jul 31, 2012 |
|---|---|---|---|---|---|---|---|---|
| Cash Flows from Operating Activities | ||||||||
| Net loss for the period | — | — | — | — | — | — | (1,133,126) | — |
| Gain on settlement of accrued expenses | — | — | — | — | — | — | 0 | — |
| Amortization of debt discount | — | — | — | — | — | — | 3,403 | — |
| Change in fair value of derivative liability | — | — | — | — | — | — | 25 | — |
| Amortization of deferred financing costs | — | — | — | — | — | — | 2,917 | — |
| Net loss | — | (387,036) | — | (1,885,445) | (1,925,179) | (23,307,064) | — | — |
| Loss on change in derivative liabilities | — | — | — | 393,718 | (58,080) | 2,918,856 | — | — |
| Gain on recission of token agreements | — | — | — | — | 0 | (7,651,981) | — | — |
| Initial loss on derivative liabilities | — | — | — | — | (12,180) | 1,132,259 | — | — |
| Net loss | (811,562) | — | (1,518,929) | — | — | — | — | (241,552) |
| Gain on settlement of accrued expenses | — | — | — | — | — | — | — | 0 |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||||||||
| Loss (gain) on change in derivative liabilities | 125,444 | (184,143) | (327,501) | — | — | — | — | — |
| Interest Expense | — | 0 | 14,682 | 277,845 | 426,376 | 0 | — | — |
| Increase in note due to penalties | — | — | — | — | 0 | 33,932 | — | — |
| Impairment expense | — | — | — | — | 0 | 2,429,981 | — | — |
| Income Tax Expense | — | — | — | — | 438,434 | 23,822,476 | — | — |
| Stock based compensation | — | — | — | 115,692 | — | — | — | — |
| Stock-Based Compensation Expense | 222,000 | 87,170 | 836,788 | — | — | — | 214,167 | — |
| Loss on stock issuance | — | — | — | — | — | — | 760,000 | — |
| Convertible loan increase due to default | — | — | 0 | 179,960 | — | — | — | — |
| Gain on settlement of debt | — | (1,460) | — | — | — | — | — | — |
| Gain on settlement of debt | 0 | — | — | — | — | — | — | — |
| Depreciation Expense | 1,397 | 1,393 | 12,334 | 16,370 | 20,114 | 25,558 | — | — |
| Imputed interest | — | — | — | — | 0 | 1,822 | — | — |
| Imputed interest | — | — | 0 | — | — | — | — | — |
| Interest Expense | — | — | 0 | 0 | 165,000 | 37,500 | — | — |
| Changes in operating assets and liabilities | ||||||||
| Increase in inventory | 0 | 25 | 805 | (830) | — | — | — | — |
| Increase (decrease) in prepaid assets | — | 39,686 | — | (4,586) | 140,250 | 0 | — | — |
| Decrease in prepaid assets | 970 | — | (36,070) | — | — | — | 13,463 | (13,947) |
| Change in Accrued Liabilities | — | — | — | — | — | — | 25,823 | (4,201) |
| Change in Accounts Receivable | — | — | — | — | — | — | 2,082 | — |
| Net Cash from Operating Activities | — | — | — | — | — | — | 0 | 1,200 |
| Increase in accounts payable and accrued expenses | 196,081 | 355,948 | 610,244 | (86,239) | 426,514 | 16,930 | — | — |
| Increase (decrease) in accounts payable related party | — | — | (11,270) | — | — | — | — | — |
| Increase (decrease) in contingent liability | — | — | 0 | 100,000 | — | — | — | — |
| Change in Accounts Payable | 82,397 | 2,985 | — | 505,038 | (209,182) | 209,928 | — | — |
| Net cash used in operating activities | (183,273) | (85,432) | (418,917) | (388,477) | (587,933) | (329,803) | (111,246) | (258,500) |
| Acquisition of license agreement | — | — | — | — | — | — | 0 | (175,000) |
| Purchase of Silver assets | — | — | — | (152,785) | 0 | (1,195) | — | — |
| Increase in short-term investments | — | — | — | — | 0 | 0 | — | — |
| Purchase of silver | — | — | 0 | — | — | — | — | — |
| Net Cash from Investing Activities | — | 0 | 0 | (152,785) | 0 | (1,195) | 0 | (175,000) |
| Cash Flows provided by Financing Activities | ||||||||
| Proceeds from Debt Issuance | 85,985 | 36,002 | 102,881 | 91,081 | 128,522 | 120,153 | — | — |
| Payments on related party debts | — | — | — | (78,428) | (149,081) | (175,500) | — | — |
| Payments on related party advances | (527) | (50,592) | (54,562) | — | — | — | — | — |
| Stock Repurchases (Issuances) | 0 | 100,000 | 147,000 | 506,500 | — | — | 0 | 500,000 |
| Repurchase of common stock | — | 0 | (97,500) | — | — | — | — | — |
| Proceeds from sale of preferred stock | — | — | 0 | 300,000 | — | — | — | — |
| Proceeds from Debt Issuance | — | — | 25,000 | — | — | — | — | 58,437 |
| Proceeds from convertible note payable | — | — | — | — | — | — | 25,000 | — |
| Deferred financing costs | — | — | — | — | — | — | (5,000) | — |
| Offering costs | — | — | — | — | — | — | 0 | (68,491) |
| Net Cash from Financing Activities | — | — | — | — | — | — | 0 | — |
| Repayments of convertible notes payable | — | — | 0 | — | — | — | — | — |
| Proceeds from Debt Issuance | — | 0 | — | 0 | 163,499 | 766,380 | — | — |
| Proceeds from loans | — | — | — | 0 | 288,014 | 0 | — | — |
| Payments on loans | — | — | — | — | (117,333) | (65,453) | — | — |
| Repayments of convertible notes payable | — | — | — | (25,000) | — | — | — | — |
| Proceeds from Stock Issuance | 97,840 | — | — | — | — | — | — | — |
| Net cash provided by financing activities | 183,298 | 85,410 | 122,819 | 794,153 | 313,621 | 645,580 | 70,000 | 489,946 |
| Net increase (decrease) in Cash | — | — | — | — | (274,312) | 314,582 | (41,246) | 56,446 |
| Cash, beginning of period | — | — | — | — | — | 15,200 | 56,446 | 0 |
| Cash, end of period | — | — | — | — | — | — | 15,200 | 56,446 |
| Net decrease in Cash | — | — | (296,098) | — | — | — | — | — |
| Net decrease in Cash | 25 | (22) | — | 252,891 | — | — | — | — |
| Beginning cash balance | — | — | 296,130 | 43,239 | 317,551 | 2,969 | — | — |
| Ending cash balance | — | — | — | 296,130 | 43,239 | 317,551 | — | — |
| Beginning cash balance | 10 | 32 | 296,130 | — | — | — | — | — |
| Ending cash balance | 35 | 10 | 32 | — | — | — | — | — |
| Supplemental disclosure of cash flow information | ||||||||
| Derivative liability written off to additional paid in capital | — | — | 0 | — | — | — | — | — |
| Interest Expense | — | 0 | — | 0 | 0 | 0 | 0 | 0 |
| Cash paid for tax | — | 0 | — | 0 | 0 | 0 | 0 | 0 |
| Conversion of note payable - related party and accrued interest to contributed capital | — | — | — | — | — | — | 0 | 0 |
| Forgiveness of shareholder debt and accrued interest | — | — | — | — | — | — | 0 | 80,991 |
| License fee payable issued for acquisition of license agreement | — | — | — | — | — | — | 0 | 525,000 |
| Forgiveness of debt recorded as reduction of intangible assets | — | — | — | — | — | — | 350,000 | — |
| Derivative liability recorded in connection with convertible debt | — | — | — | — | — | — | 20,420 | — |
| Silver used to settle debt | — | 152,785 | — | — | — | — | — | — |
| Interest Expense | 0 | — | — | — | — | — | — | — |
| Income Tax Expense | 0 | — | — | — | — | — | — | — |
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Derivative Liability written off to additional paid in capital | — | — | — | 128,001 | — | — | — | — |
| Shares issued for the conversion of notes payable | — | — | — | 101,500 | — | — | — | — |
| Silver used to settle debt | 0 | — | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.